Returns | 1W : -2% , 1M : 1.5%,1Y : 27.9% |
LT :   |
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
HIKAL LTD | -2% | 1.5% | 27.9% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -1.6% | -0.6% | 27.8% |
DR REDDYS LABORATORIES LTD | -0.1% | -2.3% | 65.7% |
DIVIS LABORATORIES LTD | -0.9% | -4.8% | 86.8% |
CIPLA LTD | 1.8% | 0.4% | 73.9% |
BIOCON LTD | -15.3% | -20.6% | 33.9% |
AUROBINDO PHARMA LTD | 8% | 9.8% | 88.7% |
LUPIN LTD | -0.8% | 10.8% | 46.3% |
TORRENT PHARMACEUTICALS LTD | -4.2% | -5.3% | 33.1% |
Ratio | Value |
---|---|
P/E P/B P/S |
24.64
P/E Calculated based on EPS of 6.85
[ Mar2020 - Standalone Results ] 2.55
P/B Calculated based on Book Value of 66.22
[ Mar2020 - Standalone Results ] 1.43
P/S Calculated based on Revenues of 1456.87 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
17% -7% 17% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |